Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials

Authors

• Rahib K. Islam, LSU Health Sciences Center – New OrleansFollow
• Lacey M. Falgout, Tulane University School of Medicine, New Orleans, LA
• Nicholas J. Culotta, LSU Health Sciences Center – New OrleansFollow
• Christopher J. Sayed, University of North Carolina at Chapel Hill, Chapel Hill, NC
• Christopher J. Haas, LSU Health Sciences Center – New OrleansFollow

Document Type

Letter to the Editor

Publication Date

8-21-2026

Publication Title

Journal of the American Academy of Dermatology

First Page

1

Last Page

2

PubMed ID

42628802

Rights

© 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.

Recommended Citation

Islam, Rahib K.; Falgout, Lacey M.; Culotta, Nicholas J.; Sayed, Christopher J.; and Haas, Christopher J., "Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials" (2026). School of Medicine Faculty Publications. 5242.
https://digitalscholar.lsuhsc.edu/som_facpubs/5242
10.1016/j.jaad.2026.06.153